{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:53:58Z","timestamp":1792601638527,"version":"4.5.0"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2014,3,13]],"date-time":"2014-03-13T00:00:00Z","timestamp":1394668800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0091080","type":"journal-article","created":{"date-parts":[[2014,3,13]],"date-time":"2014-03-13T16:54:51Z","timestamp":1394729691000},"page":"e91080","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":63,"title":["High-Density Lipoprotein Cholesterol Is a Favorable Prognostic Factor and Negatively Correlated with C-Reactive Protein Level in Non-Small Cell Lung Carcinoma"],"prefix":"10.1371","volume":"9","author":[{"given":"Pei-Dong","family":"Chi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,3,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"A Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/annonc\/mdl498","article-title":"Estimates of the cancer incidence and mortality in Europe in 2006","volume":"18","author":"J Ferlay","year":"2007","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/jnci\/djn483","article-title":"Biomarker studies abound for early detection of lung cancer","volume":"101","author":"V Brower","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s005990070013","article-title":"Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects","volume":"30","author":"AM Fiorenza","year":"2000","journal-title":"Int J Clin Lab Res"},{"key":"ref5","first-page":"307","article-title":"Serum HDL cholesterol concentration in patients with squamous cell and small cell lung cancer","volume":"6","author":"K Siemianowicz","year":"2000","journal-title":"Int J Mol Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1002\/1097-0142(19871215)60:12<3065::AID-CNCR2820601234>3.0.CO;2-Q","article-title":"Serum lipids and lipoprotein disorders in cancer patients","volume":"60","author":"CG Alexopoulos","year":"1987","journal-title":"Cancer"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000196195","article-title":"Decreases in serum cholesterol levels in advanced lung cancer","volume":"60","author":"S Umeki","year":"1993","journal-title":"Respiration"},{"key":"ref8","first-page":"483","article-title":"Association between high-density lipoprotein cholesterol and breast cancer varies by menopausal status","volume":"7","author":"PG Moorman","year":"1998","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/1097-0142(19940115)73:2<253::AID-CNCR2820730204>3.0.CO;2-F","article-title":"Cholesterol content in tumor tissues is inversely associated with high-density lipoprotein cholesterol in serum in patients with gastrointestinal cancer","volume":"73","author":"S Dessi","year":"1994","journal-title":"Cancer"},{"key":"ref10","first-page":"119","article-title":"The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics","volume":"4","author":"PM Cruz","year":"2013","journal-title":"Front Pharmacol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1002\/jcp.22570","article-title":"Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib","volume":"226","author":"ME Irwin","year":"2011","journal-title":"J Cell Physiol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.lungcan.2009.10.014","article-title":"Lipid raft modulation inhibits NSCLC cell migration through delocalization of the focal adhesion complex","volume":"69","author":"JH Jeon","year":"2010","journal-title":"Lung Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1158\/1055-9965.EPI-08-1248","article-title":"Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer","volume":"18","author":"J Ahn","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2188\/jea.JE20130006","article-title":"High-density lipoprotein and prostate cancer: an overview","volume":"23","author":"K Kotani","year":"2013","journal-title":"J Epidemiol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clnu.2004.08.004","article-title":"Dyslipidemia and inflammation: an evolutionary conserved mechanism","volume":"24","author":"E Esteve","year":"2005","journal-title":"Clin Nutr"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"LM Coussens","year":"2002","journal-title":"Nature"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2143\/AC.58.1.2005253","article-title":"Hyperlipidaemias and serum cytokines in patients with coronary artery disease","volume":"58","author":"K Mizia-Stec","year":"2003","journal-title":"Acta Cardiol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2337\/diabetes.51.4.1088","article-title":"Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study","volume":"51","author":"E van Exel","year":"2002","journal-title":"Diabetes"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/01.CIR.97.11.1029","article-title":"Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study","volume":"97","author":"J Jeppesen","year":"1998","journal-title":"Circulation"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2796.1996.53873000.x","article-title":"Lipoprotein lipase in relation to inflammatory activity in rheumatoid arthritis","volume":"240","author":"S Wallberg-Jonsson","year":"1996","journal-title":"J Intern Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1158\/0008-5472.CAN-07-0212","article-title":"Serum high-density lipoprotein cholesterol and risk of non-hodgkin lymphoma","volume":"67","author":"U Lim","year":"2007","journal-title":"Cancer Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1203\/00006450-199308000-00011","article-title":"Circulating tumor necrosis factor-alpha levels and lipid abnormalities in patients with cystic fibrosis","volume":"34","author":"E Levy","year":"1993","journal-title":"Pediatr Res"},{"key":"ref23","first-page":"1045","article-title":"Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome","volume":"74","author":"C Grunfeld","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"ref24","first-page":"749","article-title":"[Analysis of basic data of the study on prevention and treatment of COPD and chronic cor pulmonale]","volume":"21","author":"X Cheng","year":"1998","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/00132577-200512000-00018","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute scientific statement: Executive Summary","volume":"4","author":"SM Grundy","year":"2005","journal-title":"Crit Pathw Cardiol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"SB Edge","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","article-title":"The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours","volume":"2","author":"P Goldstraw","year":"2007","journal-title":"J Thorac Oncol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1161\/01.CIR.0000055014.62083.05","article-title":"C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women","volume":"107","author":"PM Ridker","year":"2003","journal-title":"Circulation"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.lungcan.2008.01.015","article-title":"HDL-cholesterol and the incidence of lung cancer in the Atherosclerosis Risk in Communities (ARIC) study","volume":"61","author":"AM Kucharska-Newton","year":"2008","journal-title":"Lung Cancer"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1245\/s10434-007-9401-0","article-title":"Serum HDL-C as a potential biomarker for nodal stages in gastric cancer","volume":"14","author":"E Guo","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00075197-200503000-00007","article-title":"Current understanding of the metabolism and biological actions of HDL","volume":"8","author":"A von Eckardstein","year":"2005","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1161\/01.RES.0000170946.56981.5c","article-title":"New insights into the regulation of HDL metabolism and reverse cholesterol transport","volume":"96","author":"GF Lewis","year":"2005","journal-title":"Circ Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1158\/1535-7163.MCT-11-0905","article-title":"HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer","volume":"11","author":"F Su","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"19997","DOI":"10.1073\/pnas.1009010107","article-title":"Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer","volume":"107","author":"F Su","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nbt0604-641","article-title":"EGFR inhibitors square off at ASCO","volume":"22","author":"M Baker","year":"2004","journal-title":"Nat Biotechnol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1634\/theoncologist.10-7-461","article-title":"FDA drug approval summary: erlotinib (Tarceva) tablets","volume":"10","author":"MH Cohen","year":"2005","journal-title":"Oncologist"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1158\/1078-0432.CCR-07-1354","article-title":"U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens","volume":"14","author":"RM Giusti","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref39","first-page":"F177","article-title":"[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives]","volume":"94","author":"A Italiano","year":"2007","journal-title":"Bull Cancer"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10555-010-9201-z","article-title":"Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy","volume":"29","author":"AF Gazdar","year":"2010","journal-title":"Cancer Metastasis Rev"},{"key":"ref41","first-page":"125","article-title":"Docetaxel-carboplatin in combination with erlotinib and\/or bevacizumab in patients with non-small cell lung cancer","volume":"6","author":"E Boutsikou","year":"2013","journal-title":"Onco Targets Ther"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","article-title":"Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)","volume":"29","author":"M Fukuoka","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1586\/14737140.8.4.605","article-title":"Inflammation in the development of lung cancer: epidemiological evidence","volume":"8","author":"EA Engels","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/bmj.321.7257.323","article-title":"Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies","volume":"321","author":"R Peto","year":"2000","journal-title":"BMJ"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1161\/01.ATV.0000023228.90866.29","article-title":"Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and apoA-I in response to inflammation in human apoA-I transgenic mice","volume":"22","author":"UJ Tietge","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1200\/JCO.2006.07.1381","article-title":"C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study","volume":"24","author":"C Siemes","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/07853890510007322","article-title":"The double jeopardy of HDL","volume":"37","author":"M Navab","year":"2005","journal-title":"Ann Med"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0091080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T08:41:35Z","timestamp":1565253695000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0091080"}},"subtitle":[],"editor":[{"given":"Antonio","family":"Moschetta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,3,13]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0091080","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,13]]}}}